Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

7.630 -0.070 (-0.91%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,624,839
Open	7.690
Bid (Size)	7.550 (100)
Ask (Size)	7.670 (1,000)
Prev. Close	7.700
Today's Range	7.530 - 7.690
52wk Range	6.000 - 11.31
Shares Outstanding	185,583,896
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today? ↗

December 12, 2025

Via Stocktwits

Why Dyne Therapeutics Stock Was Crushing it This Week ↗

November 21, 2025

The company has solid potential with its development of drugs targeting muscle disorders.

Via The Motley Fool

Performance

YTD	-2.6%	-2.6%
1 Month	+11.4%	+11.4%
3 Month	-0.3%	-0.3%
6 Month	-21.0%	-21.0%
1 Year	-1.2%	-1.2%

More News

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

November 12, 2025

From Astria Therapeutics, Inc.

Via Business Wire

BioCryst (BCRX) Q3 2025 Earnings Call Transcript ↗

November 03, 2025

Via The Motley Fool

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play ↗

October 14, 2025

Via Stocktwits

BioCryst To Acquire Astria Therapeutics In $700M Deal ↗

October 14, 2025

Via Stocktwits

Earnings Scheduled For August 4, 2025 ↗

August 04, 2025

Via Benzinga

Earnings Outlook For BioCryst Pharma ↗

August 01, 2025

Via Benzinga

Top Stocks With Earnings This Week: Joby, IonQ, AMD and More ↗

November 03, 2025

Via Benzinga

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Posts Mixed Q3 2025 Results, Beats on EPS But Misses Revenue ↗

November 03, 2025

Via Chartmill

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sotherly Hotels Inc. (Nasdaq – SOHO), Hologic, Inc. (Nasdaq – HOLX), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)

October 27, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hologic, Inc. (Nasdaq – HOLX), TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)

October 21, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH), SWK Holdings Corporation (Nasdaq – SWKH)

October 16, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 14, 2025

Via Benzinga

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate' ↗

October 14, 2025

Via Benzinga

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

October 14, 2025

From Astria Therapeutics, Inc.

Via Business Wire

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Via MarketMinute

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder ↗

August 21, 2025

Via Benzinga

BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level ↗

August 04, 2025

Via Stocktwits

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Exceeds Q2 2025 Expectations with Robust Revenue and Profit Growth ↗

August 04, 2025

Via Chartmill

BioCryst (BCRX) Q2 Revenue Jumps 50% ↗

August 04, 2025

Via The Motley Fool

BioCryst Just Ditched Its Europe Business — Here's Why Investors Are Cheering ↗

June 27, 2025

Via Benzinga

BioCryst To Sell European Business Of Its Hereditary Angioedema Drug To Pay Off Debt: Stock Rises While Retail Stays Bearish ↗

June 27, 2025

Via Stocktwits

BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) – A Strong Growth Candidate Meeting Minervini’s Criteria ↗

June 03, 2025

Via Chartmill

Frequently Asked Questions

Is BioCryst Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, BioCryst Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does BioCryst Pharmaceuticals, Inc. - Common Stock trade on?

BioCryst Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for BioCryst Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for BioCryst Pharmaceuticals, Inc. - Common Stock is BCRX on the Nasdaq Stock Market

What is the current price of BioCryst Pharmaceuticals, Inc. - Common Stock?

The current price of BioCryst Pharmaceuticals, Inc. - Common Stock is 7.630

When was BioCryst Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of BioCryst Pharmaceuticals, Inc. - Common Stock was at 12/26/25 04:00 PM ET

What is the market capitalization of BioCryst Pharmaceuticals, Inc. - Common Stock?

The market capitalization of BioCryst Pharmaceuticals, Inc. - Common Stock is 1.42B

How many shares of BioCryst Pharmaceuticals, Inc. - Common Stock are outstanding?

BioCryst Pharmaceuticals, Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.